Published in J Oncol Pract on January 01, 2008
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA (2007) 14.54
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol (2006) 4.70
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol (2003) 4.56
Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol (2007) 3.86
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol (2005) 1.78
A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2007) 1.53
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer (2005) 1.34
Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev (2006) 1.15
International network of cancer genome projects. Nature (2010) 20.35
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 5.56
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med (2011) 4.10
Therapeutic advances in pancreatic cancer. Gastroenterology (2013) 2.17
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol (2005) 1.78
A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2007) 1.53
Pancreatic adenocarcinoma. J Natl Compr Canc Netw (2010) 1.52
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol (2009) 1.38
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs (2008) 1.30
Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer (2003) 1.26
Pancreatic cancer in mice and man: the Penn Workshop 2004. Cancer Res (2006) 1.24
Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas (2008) 1.15
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol (2010) 1.15
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest (2008) 0.94
Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J (2012) 0.87
Treatment of metastatic pancreatic cancer. J Natl Compr Canc Netw (2005) 0.87
Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2005) 0.85
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol (2012) 0.84
Systemic therapy for pancreatic cancer. Semin Radiat Oncol (2005) 0.82
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol (2012) 0.82
Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology (2008) 0.81
HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR Biomed (2014) 0.81
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas (2016) 0.78
Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. J Nucl Med (2002) 0.76
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2017) 0.76
Current and future strategies for combined-modality therapy in pancreatic cancer. Curr Oncol Rep (2002) 0.75
Minutes of the Business Meeting of the American Pancreatic Association, Friday, October 28, 2016, Boston, Massachusetts. Pancreas (2017) 0.75
Minutes of the Business Meeting of the American Pancreatic Association, Friday, November 6, 2015, San Diego, California. Pancreas (2016) 0.75
Combination therapy for non-Hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practice. J Am Pharm Assoc (Wash) (2002) 0.75
Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas (2016) 0.75